A clinical analysis from the Bio ImPAcT Consortium reports low biosimilar adoption in Ireland is limiting potential oncology savings and patient access. While biosimilars account for roughly 52–54% of oncology biologics in Ireland, uptake remains substantially behind several European peers where penetration is consistently above 90%. The paper frames the issue as policy execution rather than drug availability, tying underutilization to higher system costs and potential inequities in access to modern biologics. For healthcare economists and payers, the work adds evidence that market design, prescribing incentives, and implementation support can materially alter real-world biosimilar utilization. The implications for manufacturers and partners are twofold: competitive pricing alone does not guarantee uptake, and policy mechanisms can accelerate or stall market penetration. For clinicians, the focus is on maintaining clinical outcomes while shifting toward lower-cost alternatives. Overall, the analysis highlights an immediate systems-level lever for reducing financial toxicity in oncology budgets without changing efficacy standards.
Get the Daily Brief